Publicação
Tirzepatide: The Beginning of a New Era on Diabetes Treatment
| Resumo: | The prevalence of obesity and, consequently, diabetes has been increasing exponentially in recent decades, on a global scale, and this trend is expected to continue in the coming years. Therefore, there is an urgent need for new therapies to help us change this trajectory. Tirzepatide, the first of a new pharmacological class named co-agonists or dual agonists of the glucagon-like peptide-1 (GLP-1) and the glucose-dependent insulinotropic peptide (GIP), has demonstrated in clinical trials published in the last two years, to significantly reduce blood glucose, improve insulin resistance and reduce body weight, with additional benefits on hypertension and lipid profile. Additional data on its impact on cardiovascular endpoints are eagerly awaited. In this article it is presented a review of this new drug and the new perspectives that its appearance will open, in the future of the treatment of diabetes and obesity |
|---|---|
| Autores principais: | Raimundo, Anabela |
| Assunto: | Diabetes Mellitus Tipo 2 Obesidade Peptídeo 1 Semelhante ao Glucagon Polipeptídeo Inibidor Gástrico Receptor do Peptídeo Semelhante ao Glucagon 1 Tirzepatide Diabetes Mellitus, Type 2 Gastric Inhibitory Polypeptide Glucagon-Like Peptide 1 Glucagon-Like Peptide-1 Receptor Obesity Tirzepatide |
| Ano: | 2023 |
| País: | Portugal |
| Tipo de documento: | artigo |
| Tipo de acesso: | unknown |
| Instituição associada: | Sociedade Portuguesa de Medicina Interna |
| Idioma: | português |
| Origem: | Revista Portuguesa de Medicina Interna |
| Resumo: | The prevalence of obesity and, consequently, diabetes has been increasing exponentially in recent decades, on a global scale, and this trend is expected to continue in the coming years. Therefore, there is an urgent need for new therapies to help us change this trajectory. Tirzepatide, the first of a new pharmacological class named co-agonists or dual agonists of the glucagon-like peptide-1 (GLP-1) and the glucose-dependent insulinotropic peptide (GIP), has demonstrated in clinical trials published in the last two years, to significantly reduce blood glucose, improve insulin resistance and reduce body weight, with additional benefits on hypertension and lipid profile. Additional data on its impact on cardiovascular endpoints are eagerly awaited. In this article it is presented a review of this new drug and the new perspectives that its appearance will open, in the future of the treatment of diabetes and obesity |
|---|
Atividades financiadas
Não foram encontrados projetos financiados.